Answers are grounded in this paper and cite their sources.
OBJECTIVE: Around 40% of patients with chronic liver disease (CLD) have a history of tobacco smoking, but the impact of smoking on fibrosis progression remains unclear. This study investigates the association between tobacco smoking and Fibrosis-4 Index (FIB-4) risk progression high-risk FIB-4 in primary care patients with CLD. METHODS: We conducted a retrospective cohort study of primary care patients with CLD and inputs for at least two separate FIB-4 calculations. Patients with an initial FIB-4 ≥3.25, or prior diagnoses of cirrhosis, hepatocellular carcinoma, or liver transplant were excluded. The primary outcome was time to FIB-4 ≥3.25, indicating a high-risk for advanced fibrosis. Tobacco smoking status (never, former, current) was the primary exposure. We used univariate and bivariate analyses to describe the cohort and unadjusted and adjusted Cox regression models to evaluate the association of tobacco smoking with time to FIB-4 ≥3.25. RESULTS: The cohort had 2547 patients, with 24%, 36%, and 41% identified as current, former, and never tobacco smokers, respectively. After a mean follow-up of 5.4 years, 24% of the cohort progressed to high-risk FIB-4. In unadjusted Cox models, former (HR 1.35; 95% CI 1.11-1.63) and current (HR 1.49; 95% CI 1.21-1.83) tobacco smoking were associated with an increased risk of progression to high-risk FIB-4. Current (HR 1.27; 95% CI 1.02-1.59), but not former (HR 1.18; 95% CI 0.97-1.43), tobacco smoking was significantly associated with time to a high-risk FIB-4 after adjusting for CLD etiology, cardiometabolic, and demographic variables. CONCLUSION: Current tobacco smoking is associated with progression to a FIB-4 at high-risk for advanced fibrosis in patients with CLD.
No takes yet. Share an insight, caveat, or question.
Wray et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: